Gapping down
In reaction to disappointing earnings/guidance: PRO -15.4%, AMD -10.5%, NOW -9.3%, STRM -9.3%, MTW -5.8%, TC -4.5%, AXP -1.8%, CCK -1.2%, HON -0.6%, DB -2.9%, ING -2.6%, SAN -2.5%, BBVA -2.1%
Other news: ATHX -52.2% (interim results from its MultiStem study in which the therapy failed to meet primary or secondary endpoints), DSCO -21.7% (completes enrollment of AEROSURF Phase 2a Clinical Trial and restructures its business to focus on development of AEROSURF and Aerosolized KL4 Surfactant pipeline ), MNGA -7.1% (provides statement regarding accident at its Tarpon Springs, Florida facility), WPCS -5.2% (following a Special Meeting the Board determined it was in the best interests of the Company to effect a reverse split of the issued and outstanding common stock at a ratio of 1-for-22), AKBA -5.2% (prices 7,272,727 shares of common stock at $8.25 per share), SNE -4.8% (following NPD data), TC -4.5% (reported Q1 total concentrate production for Mount Milligan was 30.3 thousand dry tonnes, with 15.4 mln pounds of payable copper and 46.k ounces of payable gold), WUBA -4.5% (acquires strategic stake in Ganji.com and announces additional investment by Tencent (TCEHY)), ASND -3.5% ( discloses that its collaboration partner, Sanofi (SNY) has decided to cease development of TransCon Insulin ), PTX -1.7% (priced its private offering of $130 mln aggregate principal amount of the Company's 4.25% Convertible Senior Notes due 2021 ), PBR -1.6% (announces that its oil and natural gas output in Brazil), QGEN -1.5% (still checking), WYNN -1.5% (Steve Wynn responds to recent press release by Elaine Wynn)
Analyst comments: MT -3.7% (downgraded to Underperform from Neutral at Exane BNP Paribas), HAIN -3.5% (downgraded to Neutral from Buy at Longbow ), ZUMZ -2.5% (downgraded to Neutral from Buy at B. Riley & Co), FLS -1.4% (downgraded to Perform from Outperform at Oppenheimer), LION -1.2% (downgraded to Mkt Perform from Outperform at Keefe Bruyette), FUL -1.1% (downgraded to Equal-Weight from Overweight at First Analysis Sec), RGA -1% (downgraded to Mkt Perform from Outperform at Raymond James), TRV -0.8% (downgraded to Equal Weight from Overweight
)
In reaction to disappointing earnings/guidance: PRO -15.4%, AMD -10.5%, NOW -9.3%, STRM -9.3%, MTW -5.8%, TC -4.5%, AXP -1.8%, CCK -1.2%, HON -0.6%, DB -2.9%, ING -2.6%, SAN -2.5%, BBVA -2.1%
Other news: ATHX -52.2% (interim results from its MultiStem study in which the therapy failed to meet primary or secondary endpoints), DSCO -21.7% (completes enrollment of AEROSURF Phase 2a Clinical Trial and restructures its business to focus on development of AEROSURF and Aerosolized KL4 Surfactant pipeline ), MNGA -7.1% (provides statement regarding accident at its Tarpon Springs, Florida facility), WPCS -5.2% (following a Special Meeting the Board determined it was in the best interests of the Company to effect a reverse split of the issued and outstanding common stock at a ratio of 1-for-22), AKBA -5.2% (prices 7,272,727 shares of common stock at $8.25 per share), SNE -4.8% (following NPD data), TC -4.5% (reported Q1 total concentrate production for Mount Milligan was 30.3 thousand dry tonnes, with 15.4 mln pounds of payable copper and 46.k ounces of payable gold), WUBA -4.5% (acquires strategic stake in Ganji.com and announces additional investment by Tencent (TCEHY)), ASND -3.5% ( discloses that its collaboration partner, Sanofi (SNY) has decided to cease development of TransCon Insulin ), PTX -1.7% (priced its private offering of $130 mln aggregate principal amount of the Company's 4.25% Convertible Senior Notes due 2021 ), PBR -1.6% (announces that its oil and natural gas output in Brazil), QGEN -1.5% (still checking), WYNN -1.5% (Steve Wynn responds to recent press release by Elaine Wynn)
Analyst comments: MT -3.7% (downgraded to Underperform from Neutral at Exane BNP Paribas), HAIN -3.5% (downgraded to Neutral from Buy at Longbow ), ZUMZ -2.5% (downgraded to Neutral from Buy at B. Riley & Co), FLS -1.4% (downgraded to Perform from Outperform at Oppenheimer), LION -1.2% (downgraded to Mkt Perform from Outperform at Keefe Bruyette), FUL -1.1% (downgraded to Equal-Weight from Overweight at First Analysis Sec), RGA -1% (downgraded to Mkt Perform from Outperform at Raymond James), TRV -0.8% (downgraded to Equal Weight from Overweight
)